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Both procainamide and lidocaine are useful for
acutely treating cardiac arrhythmias, and procainamide can be useful in chronic antiarrhythmic regimens. Successful management of cardiac arrhythmias
requires knowledge of: 1) the mechanism and natural history of the arrhythmia, 2) the physiologic
state of the patient, and 3) the cardiac effects, pharmacodynamics, and general pharmacology of the
antiarrhythmic drugs.
Although often done, it is foolhardy to undertake treatment of a cardiac arrhythmia without a
precise diagnosis. The rationalization for such an undertaking frequently is that, no matter which of several possible arrhythmias is at hand, the treatment to
be initiated would be beneficial or at least not harmful
for any. This rationalization is often invoked to avoid
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the considerable effort which may be required in order to precisely diagnose the nature of the arrhythmia. There are many specific cases where one not
only treats a harmless arrhythmia, or, by not making
a diagnosis, fails to use the correct therapy, but also
employs a therapy which is actually harmful. Figure
1 shows an example of unnecessary therapy on the
basis of an error in diagnosis. This patient had occasional ventricular premature depolarizations (VPD's).
T he VPD's were often followed by an aberrantly
conducted beat of supraventricular origin. These
couplets of wide QRS's were incorrectly considered
to be salvos of VPD's and were treated with lidocaine. In fact, the patient had no indication for antiarrhythmic drug therapy at all. As luck would have
it, lidocaine caused undesirable central nervous system effects in this patient. As mentioned above, therapy may be not only inappropriate but also damaging. For example, patients with atrial flutter with
variable A-V conduction not infrequently show wide
aberrant beats. In intensive care units, these are often
mistakenly called VPD's. The fact that a non-standard bipolar chest lead is used for monitoring may
obscure the fact that the beat has a RBBB configuration, a finding which might lead the physician to
suspect aberrant conduction. Also, treatment may be
initiated on the basis of observation of the rhythm
on the oscilloscope screen. Thus, the physician may
overlook the typical group beating of the Gouaux65
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Fig. ]- Incorrect interpretation of rhythm leading to unnecessary therapy. The upper panel shows lead I of the ECG which was
incorrectly interpreted as salvos of VPD'~, and on this basis li docaine was begun.
The lower panel shows recordi ngs fro m hi gh right atrium (HR A), the bundle of H is (H BE), and lead I of the ECG . Actually,
t he r hythm was occasional VPD's with concealed retrograde conduction resulting in a berrant co nductio n of the su bseq uent bea t
(LBBB config uration).
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Ashman phenomenon which would have been more
obvious in analyzing a paper recording. This combination of errors in the intensive care unit can
cause aberrant beats to be treated with lidocaine.
Lidocaine can slow the atrial rate and enhance A-V
conductivity, leading to a striking increase in ventricular rate. Lidocaine in these circumstances has
caused atrial flutter to conduct with a 1 : 1 A-V ratio
and has produced ventricular rates of nearly 300 per
minute. If the heart is hemodynamically impaired,
rapid heart rates caused in this way can be catastrophic. Other examples could be given, but these
two suffice to underscore the importance of obtaining
a correct diagnosis of the arrhythmia before embarking on a therapeutic course.
Even after precise identification, obviously, not
all arrhythmias deserve treatment with suppressant
antiarrhythmic drugs. Many arrhythmias do not deserve any therapy whatsoever. The past decade of
coronary care unit experience has taught us a great
deal about the natural history and indications for
treating arrhythmias which arise between 4 and 72
hours after onset of symptoms in acute myocardial
infarction. A great error which has become a national epidemic has been the unjustifiable extrapolation of the CCU experience to the first two hours of
infarction or of the late postinfarction period. At both
of these times the pattern arrhythmias, their meaning,
or their response to therapy seem to be very different
from arrhythmias encountered in the CCU and, at
present, less well characterized. Even worse, there is
a widespread tendency in recent years to use the same
criteria for treating arrhythmias in other etiologic
forms of heart disease as those used in acute myocardial infarction. In most forms of heart disease, our
knowledge of the meaning and natural history of arrhythmias is even more rudimentary than our knowledge of arrhythmias in various stages of coronary
heart disease. However, in many diseases, it is abundantly clear that arrhythmias do not need treatment
even though the same ECG pattern would dictate
therapy in acute myocardial infarction.
Once an arrhythmia is identified and the need
for treatment established, the regimen of therapy
may or may not require a specific antiarrhythmic
drug. Arrhythmias encountered outside the coronary
care unit very often are caused or seriously aggravated by non-cardiac factors such as electrolyte, acidbase, or blood gas derangements or drug toxicity.
When initially evaluating any cardiac arrhythmia, the
physician should consider the many possible non-
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cardiac causes and institute the appropriate clinical
and laboratory investigations to identify these, even
though temporary emergency therapy is required immediately. Not only will correction of non-cardiac
causes usually control the arrhythmia but also arrhythmias generated by electrolyte imbalance or
blood gas derangement may be highly resistant to
"specific" antiarrhythmic drugs like procainamide or
lidocaine.
When a drug is finally selected to treat an arrhythmia, the goal is to maintain the plasma concentration above the minimum effective concentration
without inadvertently producing toxic concentrations.
To successfully achieve this goal requires a considerable knowledge about the pharmacokinetics, metabolism, and excretion of the drugs utilized.
It is our purpose to discuss briefly the clinically
relevant electrophysiologic properties, clinical usage,
pharmacodynamics, and toxicity of procainamide
and lidocaine.
Electrophysiologic Properties. The following
are a few clinically relevant electrophysiologic effects
of procainamide and lidocaine.
Lidocaine. Lidocaine is a Group II antiarrhythmic drug. It suppresses automaticity in cardiac Purkinje fibers by increasing the potassium conductance
of the sarcolemma but does not significantly alter
threshold voltage. It shortens action potential duration and refractoriness in Purkinje fibers and ventricular muscle but has practically no effect on atrial
tissues . It does not alter conduction velocity or responsiveness very much in either normal atrial or
normal ventricular tissues. Under certain circumstances, lidocaine can improve conduction or reverse
conduction block in ventricular tissues. Lidocaine
depresses sinus node function less than procainamide.
Rarely, it has been reported to suppress sinus function, usually in older patients, particularly with inferior myocardial infarction and/ or preexisting signs
of sinus node dysfunction. Lidocaine has little effect
on atrial arrhythmias as might be predicted from its
lack of effect on atrial tissues from normal animals.
The drug can, but does not always, cause slight slowing of atrial rate in atrial flutter. Also, lidocaine
causes no change or decrease in A-V conduction
time and A-V refractoriness. Since the drug does not
prolong conduction in the ventricular tissues, it does
not prolong the QRS, and since it does not prolong
action potential duration in the ventricles, it does not
prolong the QT. It is still not clear how lidocaine
abolishes reentrant ventricular arrhythmias in man.
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Our studies to date suggest that it may do so either
by improving conduction throughout the reentrant
circuit or by blocking conduction in abnormal components of the circuit without affecting normal components.
Procainamide. Procainamide (like quinidine) is
a typical Group I antiarrhythmic drug. It suppresses
automaticity and moves the threshold voltage of heart
muscle toward zero. Also, it lengthens action potential duration and lengthens the refractory period of
atrial and ventricular cell types. It slows conduction
in the atrium, A-V node, and ventricle and decreases
membrane responsiveness of atrial and ventricular
fibers. Many of these actions are reflected in the
ECG. Procainamide does not usually affect the sinoatrial rate in intact man, but it can cause dramatic
slowing of sinus rhythm in patients with derangements of sinus node function. This drug often causes
minimal flattening and widening of the P wave. The
atrial rate is slowed by procainamide in atrial fibrillation and flutter, and high concentrations will convert these rhythms to sinus rhythm . A direct action
of procainamide is to slow A-V conduction and increase the refractoriness of the A-V conducting system; the magnitude of this effect is quite variable
from patient to patient under similar conditions and

is modified by many other variable factors. Administration of procainamide to treat VPD's caused by
digitalis toxicity may unpredictably produce severe
A-V conduction disturbances. Slowing of conduction
in the His-Purkinje system and in ordinary ventricular muscle caused by this drug is reflected in a widening of the QRS interval. In a given patient, QRS
width changes usually increase linearly as a function
of plasma drug concentration. The changes in repolarization produced by procainamide usually cause
prolongation of the QT interval and alteration in T
wave contour. The rather reliable change in QRS
and QT intervals has proved quite useful in estimating therapeutic and toxic cardiac effects during therapy. The profound changes procainamide causes in
conduction, responsiveness, and refractoriness of ventricular tissues no doubt underly its impressive ability to suppress VPD's or ventricular tachycardia.
Our recent experiments in man suggest that as the
plasma concentration of this drug rises, it causes a
steadily increasing depression of conduction in a ventricular reentrant circuit until conduction fails altogether and the arrhythmia is abolished.
Clinical Use. Lidocaine. Lidocaine is not effective against a wide variety of cardiac arrhythmias,
being most useful in combatting ventricular arrhyth-

TABLE 1.
Effectiveness of Lidocaine and Procainamide Against Cardiac Arrhythmias*
ARRHYTHMIA

LIDOCAINE

PROCAIN AMIDE

# of Success /# of Cases

# of Success /# of Cases

SUPRA VENTRICULAR:

Atrial premature depolarizations
Paroxysmal supraventricular tachycardia
Supraventricular tachycardia with A-V block
Atrial flutter
Atrial fibrillation
A-V junctional premature contractions
Non-paroxysmal A-V junctional tachycardia
Unspecified supraventricular tachycardia
Total:

15 / 31
5/ 11
0/ 4
0 / 11
3/ 41
4/ 8
0/ 7
3/ 9
30 / 122

(48 %)
(46 %)

8/ 13
28 / 40

(62 %)
(70 %)

( 0%)
( 7%)
(50 %)
( 0%)
(33 %)
(25 %)

14 / 53
73 / 215
9/ 13
26 / 33
14 / 23
172 / 390

(26 %)
(34 %)
(69 %)
(79 %)
(61 %)
(44%)

389 / 495
48 / 69
437 / 564

(79 %)
(70 %)
(77 %)

210 / 244
98 / 122
308 / 366

(86%)
(80 %)
(84 %)

VENTRICULAR:

Ventricular premature contractions
Ventricular tachycardia
Total:

* A comparison of clinical effectiveness of lidocaine and procainamide against supraventricular and ventricular arrhythmias.
Calculations are based on a review of the literature up to 1972 and include arrhythmias that were completely suppressed or at least
90 % improved after drug therapy. The percentage was not determined where total cases were less than five.
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mias. It is practically worthless against atrial flutter
or fibrillation (Table 1); the rare instances in which
it appears to abolish one of these rhythms may only
be due to coincidence, or to indirect effects. Lidocaine is also, as a rule, ineffective against atrial or
A-V junctional tachycardias unless they are caused
by digitalis excess. Of course, lidocaine is highly effective against ventricular arrhythmias arising in many
circumstances, but it is limited to relatively shortterm use because it must be administered parenterally.
It should be emphasized that there is considerable difference in electrophysiologic action between
procainamide and lidocaine, and it is common to see
an arrhythmia that is resistant to one, submit to the
other.
Procainamide. Procainamide is an antiarrhythmic drug of broad spectrum, effective against a wide
variety of atrial , A-V junctional, and ventricular arrhythmias (Table 1). In general , higher plasma concentrations are required to convert or prevent atrial
fibrillation than those needed to control ventricular
arrhythmias. Early in its use, this fact led to the mistaken impression that the drug was ineffective against
atrial arrhythmias. However, as will be discussed
later, procainamide has a short half-life which means
to continuously maintain plasma concentrations effective against atrial arrhythmias requires large doses
every six hours . Large doses may produce toxic peak
concentrations and necessitate more frequent dosing,
a change which is usually inconvenient for the patient. This drug is a poor choice against ventricular
arrhythmias in patients with severe A-V conduction
disturbances because it may worsen conduction. Although it can be effective against many digitalis-toxic
arrhythmias, its actions in this circumstance are too
unpredictable to warrant its use.
Prophylaxis. In very recent years, studies have
evaluated prophylactic use of procainamide or lidocaine, as well as other antiarrhythmic drugs, in the
CCU. These studies, conducted in first-rate university hospitals, fail to show a decrease in mortality in
the treated versus the control group. This might be
expected since patients with heart failure, shock,
sinus bradycardia, A-V block, or arrhythmias requiring immediate treatment were not admitted to
the studies. Furthermore, these CCU's were all wellstaffed so that sophisticated hospital-based physicians
were almost instantly available to analyze and treat
arrhythmias which developed in either the placebo
or drug-treated group . It would seem that a pa-
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tient in a university hospital CCU has little to
gain from prophylactic therapy. On the other hand ,
a patient residing in any one of the many community
hospital CCU's in this country where the staff may
be less plentiful or well-trained and the patient's
physician is based in his office practice, might have
a great deal to gain from routine prophylaxis. Prophylaxis might prevent harmful results where premonitory arrhythmias were overlooked. However,
routine prophylaxis in every case of myocardial infarction might increase the morbidity and mortality
in patients with cardiac failure or shock, or those
with bradyarrhythmias or conduction defects. Thus,
even in community hospitals, the case for routine
prophylaxis in acute myocardial infarction is not entirely clear.
Prophylaxis for arrhythmias in ambulatory, apparently well patients with coronary heart disease is
even less well-grounded than prophylaxis in acute
myocardial infarction. Several pertinent facts are
emerging. First, VPD's are extremely common in
asymptomatic coronary heart disease patients. Second , middle-aged men who have frequent VPD's
( > 10 VPD's per 1,000 beats) or sustained relative
bradycardia have a much higher incidence of sudden death in follow-up periods than their peers without one of th ese two rhythm disturbances, even
though neither group has clinically evident coronary
heart disease. What is not clear is whether any available drug can significantly and persistently reduce
the incidence of these arrhythmias for long periods
of time without undue undesirable effects. Neither is
it clear that, if one could alter these arrhythmias that
are correlated with sudden death, the incidence of
sudden death would be reduced. Thus, at present,
prophylaxis in such a population is highly experimental and should be controlled since we do not
even know that prophylaxis would do more good
than harm.
Another related area of current interest arises
from the fact that patients who die from arrhythmias
during early stages of acute myocardial infarction
or ischemia probably suffer from either ventricular
fibrillation or bradyarrhythmias. It has been suggested that patients who are known to be at risk to
myocardial ischemia, that is, patients with known
coronary heart disease, carry syringes containing
lidocaine and/ or atropine. These patients would be
advised, on experiencing symptoms of myocardial
ischemia, to inject their drug intramuscularly and
come to the hospital. Again , with the evidence avail-
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able at present, we are not certain that such a course
of action would not be more harmful than helpful,
and such therapy cannot be recommended for more
than controlled trials. However, it is reasonable to
urge immediate contact between the patient with coronary heart disease who has a change in symptoms
and the health care system. Analysis of the ECG
either transmitted by telephone or obtained by a
medical team invading the community would allow
early specific treatment on the basis of the arrhythmias encountered in the individual patient. Some
variant of this method would seem greatly preferable to self-injection of drug or drugs initiated on
the basis of symptoms alone without regard for the
presence or type of rhythm disturbance.
Pharmacodynamic Considerations. Particularly
in treatment of acute arrhythmias, one of the most
important aspects of antiarrhythmic drug therapy
is pharmacodynamics. It is necessary to maintain
the plasma drug level above the minimum effective
concentration (MEC) because life-threatening arrhythmias may emerge when plasma concentrations dip below this level. Also, the rate at which
MEC is achieved may be quite important. Knowledge of drug kinetics is even necessary in order to
assess the effectiveness of the drug being used . Lack
of a consummate knowledge of pharmacodynamics
often leads physicians to conclude that a particular
drug is ineffective in combatting a particular arrhythmia. In actuality, this conclusion is often
incorrect because the physician is unaware of the
expected time course of drug action and thus evaluates drug effectiveness at an inappropriate time.
Since many of the arrhythmias treated in emergency
situations, for example, acute myocardial infarction,
are short-lived, the need for antiarrhythmic drug
therapy is brief. Usually, a few days of such therapy
is sufficient. When discontinuing or interrupting the
antiarrhythmic drug therapy under such circumstances, knowledge of the expected course of elimination is vital. This knowledge allows maximum
intensity of observation at appropriate times without
wasting effort on unnecessarily intense vigilance at
inappropriate times.
Lidocaine. Lidocaine is only used parenterally.
This drug is very popular in treating acute ventricular arrhythmias where it is usually given as a
sudden intravenous injection. If the arrhythmia requires treatment for a few days, constant-rate IV
infusion is employed. Intramuscular injections of a
special 10 % formulation of lidocaine is being studied

by our group and others for possible use against
arrhythmias.
Brief IV injection. Empirical trial has determined that IV lidocaine doses of 0.5 to 1.5 mg per
kg body weight can be repeated every three to five
minutes until a 200 to 300 mg dose is reached.
This method is usually safe. The time course of
plasma lidocaine after an IV injection is shown in
figure 2. Several features of interest can be noted.
First, the lidocaine concentration rapidly drops below the MEC ( 15-40 minutes), and the arrhythmia
being treated may return. The early rapid drop
(t11 2 = 9 minutes) in concentration is due to distribution of the drug into its large apparent volume of
distribution (Vn = 120 liters). After distribution, the
rate of elimination slows and is accomplished by a
combination of renal excretion and hepatic metabolism. The hepatic metabolism of lidocaine is so rapid
that under ordinary circumstances, less than 5 to
10 % of lidocaine is excreted unchanged by the kidney. A note of caution about repeated IV injections
or injections during infusions: the volume of distribution is partially filled with drug under these circumstances, and an unexpectedly large increase in
plasma concentration may occur.
Intravenous constant-rate infusion. This mode
of therapy is commonly used. Figure 2 shows the
time course of the rise in plasma lidocaine when
infusion is begun without prior doses. Because the
MEC for lidocaine is usually so low ( 1 to 2µ,g per
ml) and the elimination t 11 2 so short ( 1.5 to 2
hours), the plasma concentration usually rises to
MEC within an hour. If elimination of lidocaine
is normal, a simple, empirical rule can be applied
to estimate the plasma lidocaine concentration at
steady state-the infusion rate of lidocaine in µ,g per
minute per kg body weight divided by 10 equals
the plasma concentration of lidocaine in ,µ,g per
ml, for example, an infusion of 30 µ,g per minute
per kg body weight should produce a plasma
concentration of 3.0 µ,g per ml at steady state.
Like any drug with first order kinetics, 90% of
the steady state value is achieved in 3.3 times
the t 11 2 . Most commonly, lidocaine infusions are
given following one or more IV injections as shown
in figure 3. Since the elimination t112 of lidocaine
is fairly brief, plasma lidocaine changes fairly rapidly
to a new steady state when IV infusion rate is
increased or decreased and falls rapidly when an
infusion is discontinued. Low cardiac output is associated with reduced hepatic blood flow and a
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Fig. 2- Time-plasma concentration course of lidocaine and procainamide produced by sudden 200 mg intravenous injection (left)
and constant-rate intravenous infusion (right).
After IV injection of either drug (lef t) , the early, rapid fall in plasma drug concentration is due to distr ibution of drug into its
large apparent volume of distribution (Vn). A slower late phase of disappearance is seen which is due to elimination of the drugs
by a combination of hepatic metabo lism and renal excretion. The half-time for elimi nation (t u 2e) is 1.5 hours for lidocaine and 3.5
ho urs for procainamide.
At right, the plasma concentration during and after a 12-hour constant infusion of procainamide and lidocaine into a 70 kg
pat ient. The infusion rate was selected so that after an infinite amount of time, the plasma concentration of each drug wou ld be
4 µg/ ml. For Jidocaine, t 112e = 1.5 hours, Vn = 120 liters , and infusion rate = 52.8 µg / min / kg body weight. For procainamide,
t u,e = 3.5 hours, Yn = 140 liters, and infusion rate = 26.4 µg / min / kg body weight. Primarily due to its longer elimination half-life,
a much slower rate of procainamide infusion is required to produce a 4 µg / ml steady-state plasma concentration. Because of its
longer t u 2e, procainamide takes longer to achieve 90 % of its steady-state plasma concentration (11.6 hours) than lidocaine (5.0 hours).
Also, the plasma concentration of procainamide falls slower after discontinuing the infusion.
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Fig. 3-Combined lidoca ine dosage in a 70 kg patient with
an initial IV injection of 100 mg followed immed iately by
an infusion of 52.8 µg / min/ kg body weight. The thin solid
line shows the minimum effective concentration (MEC)
for antiarrhythmic action . The thick solid line shows the
concentration-time course resulting from combined therapy.
The two interrupted lines show the concentration-time
course which would have resulted from either mode of dosing a lone. Note that this method maintains the pl asma concentration in the effective range.

reduced rate of lidocaine elimination. Also, lidocaine
elimination can be reduced when hepatocellular function is severely impaired. When congestive failure
or another condition reducing metabolism of the
drug is present, infusion rates must be reduced
accordingly-sometimes by as much as two or threefold.
Intramuscular injection. This route of administration is still being studied for its therapeutic usefulness. The plasma concentration achieved after
intramuscular injection seems to depend on the
formulation and concentration injected, the particular muscle used for injection, activity in the muscle
after injection, and general circulatory status. Using
a special 10% solution and a 4 mg per kg body
weight given in the deltoid muscle, we usually
achieve a 1 p..g per ml plasma concentration by 5
minutes, an average peak level of 3.3 µg per ml
at 15 minutes, and the concentration exceeds 1 p..g
per ml for 90 to 120 minutes (fig. 4).
Oral doses. When lidocaine is given orally, it
is well absorbed, but this route of administration
has at least two disadvantages which severely limit

its usefulness. First, the liver metabolizes an incredible proportion of an oral dose when the drug is
presented to the liver via the portal circulation,
and very low plasma concentrations of lidocaine are
achieved. Second, oral doses tend to produce significant abdominal discomfort and, very frequently,
nausea. There is evidence to suggest that the nausea
may be caused by the central action of a metabolite
rather than local gastrointestinal irritation.
Procainamide. Procainamide is a more versatile drug than lidocaine not only because of its
broader an tiarrhythmic spectrum but also because
it can be adminstered by more routes, including the
oral route which permits long-term therapy.
IV injection. There is a great deal of conflicting data in the literature regarding IV injection
of procainamide. Many reports would lead one to
believe that precipitous arterial hypotension is almost
the rule after IV procainamide. T his is true if large
injections are given. We have devised a simple
method of IV injection which allows rapid control
of ventricular rhythms but circumvents hypotension. We give 100 mg IV every five minutes. This
leads to a linear rise in plasma drug concentration and progressive decrease in VPD's until they
finally disappear. This usually takes 4 to 8 doses
and is not accompanied by clinically significant
hypotension ( fig. 5). Another advantage is that the
physician knows immediately whether or not a par-
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Fig. 4- Average pl asma lidocaine as
seven patients with acute m yoca rdial
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ticular arrhythmia will respond to this agent and
whether high or low concentrations will be required.
Like lidocaine, procainamide plasma concentration
falls rapidly after a single IV injection because of
an initial rapid distribution of the drug into a large
apparent volume (fig. 2). The late phase of decline
in plasma concentration is due to elimination and
has an average t 112 of 3.5 hours. A large proportion of procainamide is excreted unchaµged into the
urine ( about 60%), but a significant amount is
acetylated, presumably by the liver (25-30 % ).
Intravenous constant-rate infusion. We have
used this method for many years, particularly in
the intensive care unit when a stable plasma concentration is desired . Figure 2 shows the plasma
concentration of procainamide during and after an
IV infusion . Because the MEC of procainamide is
higher than lidocaine and the elimination t 11 2 is
longer ( ± 3.5 hours) , infusions may not yield therapeutic concentrations until about 6 hours have
elapsed, and 90 % of steady-state concentration
is reached at 12 hours (3.3 x 3.5 ) . Because the
elimination t 11 2 of procainamide is about twice as
long as that of lidocaine, the former drug takes
longer to achieve a new steady state after a change
in infusion rate and falls much slower when an
infusion is stopped. Figure 4 shows the combination
of intermittent IV injection therapy with constantrate infusion .
Intramuscular injection. Procainamide is fairly
well absorbed after IM injection and when given
by this route rapidly produces antiarrhythmic plasma
concentrations which decline as expected from its
elimination t 112 . The rate at which a MEC is
achieved is not a great deal faster than after an
oral dose. Therefore, unless the patient is unable
to take the drug by mouth , there is little indication
for IM administration.
Oral doses. Procainamide can be given by
mouth which is a major advantage over lidocaine.
The drug is not well absorbed from the stomach
when the pH is acid, and delay in gastric emptying
can cause a delay in onset of absorption. However,
this drug is quickly absorbed from the alkaline
small intestine; after adequate doses, effective plasma
levels are achieved in 15 minutes or so, and the
peak level is achieved between 45 and 75 minutes
after a dose. Absorption is virtually complete after
90 to 105 minutes, and elimination takes place with
a t1 ;2 of 3.5 to 4 hours. R enal excretion of procainamide is greatly reduced when the urine is alkaline,
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Fig. 5-Plasma procainamide concentration plotted as a
function of time when drug is given by incremental intravenous dosing and / or constant intravenous infusion. The
minimum effecti ve concentration , MEC, is represented by
the thin solid line. Six JOO mg doses of proc ainamide are
given every 5 minutes , block dais, until the arrhythm ia is
completely suppressed at a plasma drug concentration of
8.2 ftg / ml with in 30 minutes. The daslz-dot line shows th e
concentration-time course which wou ld have resulted if incremental doses were stopped and no other mode of dosing
started. Without prior injection , when a constant intravenous
procainamide infusion ( 42.8 µg / min lkg body weight) is
started , dashed curve, the plasma drug concentration would
be above the MEC at 3 hours and is 6.5 µg / ml at steady
state. The thick black line represents the plasma procainamide concentration which would be obtained by initially
giving the six l 00 mg injections and , then. immediately beginn in g a constant IV infusion of 42.8 ftg / min / kg body
weight. Note that the procainamide concentration never falls
below the MEC.

and in instances of congestive failure or renal failure.
In these situations, a larger proportion of a given
dose is acetylated by the liver. In congestive failure,
procainamide, like lidocaine, has a smaller apparent
volume of distribution, which means the same
amount of drug in the body will result in a higher
plasma drug concentration. Some years ago we noted
procainamide toxicity occurring during the change
from intravenous constant-rate infusions of procainamide to an oral regimen , even though the total
24-hour doses were identical. Our error is shown
in figure 6 (upper panel). Since an oral dose produces a rapid rise in plasma concentration, an initial
oral dose given immediately on stopping the infu sion
causes a high (toxic) plasma concentration. It is
apparent that an oral dose of a rapidly absorbed
drug is tantamount to an TV injection. This unfor-
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Fig. 6-Changing from continuous intravenous infusion to
an oral dose regimen of procainamide Vn
140 liters, h 1,e
4.0 hours.
The upper graph shows the termination of an intravenous infusion which for three days had maintained a
stable plasma procainamide concentration of 8 µg/ ml. At
time = 0, the infusion was discontinued and a regimen of
1,000 mg oral doses every 6 hours was begun. Note that toxic
concentrations are obtained after each of the first four oral
doses although this will ultimately be a satisfactory regimen
at steady state.
The lower graph shows an identical patient, given an
identical infusion and oral dosage regimen with only one
exception-four hours were allowed to elapse between cessation of infusion and beginning the oral drug. Note that the
plasma procainamide concentration never reaches toxic
concentrations.
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tunate sequence can be avoided completely by
waiting for about four hours after discontinuing the
infusion before giving the first oral dose (fig. 6,
lower panel).
Toxicity. While antiarrhythmic drugs have
considerably decreased mortality from arrhythmias
seen following acute myocardial infarction and open
heart surgery, improper use of these agents is as

potentially life-threatening as the presence of the
arrhythmia itself. A considerable incidence of toxicity is still encountered in using these drugs and
impairs their general usefulness. Toxicity usually
results from insufficient attention to the general
physiologic state of the patient, the functional impairment of the organs which metabolize these
drugs, or pharmacodynamic considerations. However, even when errors in judgement are made using
these drugs, a thorough knowledge of their toxic
effects and a continuing careful search for early
toxic signs can often prevent more severe and serious
toxicity.
Lidocaine. Clinical toxicity of lidocaine appears
to be related to size of dose and rate of administration. Ordinary doses, however, may produce undesirable effects when there is severe hepatic disorder,
acidosis, severe congestive heart failure, low cardiac
output, and shock. If lidocaine is infused at usual
rates where these conditions exist, toxicity may
ensue and, in fact, where blood levels have been
measured in these cases, they are frequently two
or three times higher than those needed for effective
therapy.
Lidocaine usually produces signs of central
nervous system (CNS) iqvolvement before any subjective or objective cardiovascular effects are observed. The early symptoms may be extremely subtle.
Blood levels greater than 6 µ.g per ml have been associated with dizziness, drowsiness, numbness of lips
and tongue, speech disturbances, and psychosis. At
present we suspect that many of the minor CNS
symptoms of lidocaine toxicity go unrecognizecj. as
such and are treated with diazepam or a similar agent.
More severe CNS manifestations such as tremor, convulsions, respiratory depression, and 11reflexia occur
most commonly when venous blood levels of lidocaine
are higher than 10 µ.g per ml but may be seen at
lower concentrations. Signs of CNS toxicity may
be treated by stopping lidocaine infusion and, as
a rule, symptoms will improve within 15-30 minutes, but may take several hours to completely abate.
Lidocaine-induced convulsions may require treatment with small intravenous doses of short-acting
barbiturates. High doses of barbiturate should be
avoided since their CNS depressant effects may
potentiate those of lidocaine and may result in
respiratory arrest.
The hemodynamic effects of 1 mg per kg of
lidocaine injected intravenously have been measured
by several groups. While hypotension may result
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from larger doses of lidocaine, in therapeutic doses,
there appears to be little effect on systemic arterial
ressure, ventricular contractile force, cardiac out~ut heart rate, or stroke volume in man. Thus, it
wo~ld seem that lidocaine given in this way exerts
remarkably few if any adverse effects of clinical
significance. The hemodynamic effects of lidocaine
in the shock state or after a constant intravenous
infusion are as yet unknown .
Finally, lidocaine has been suspected of producing cardiovascular toxicity. Clinical observations,
largely unsubstantiated by conclusive evidence, have
implicated lidocaine as the cause of: l) rapid ventricular response to an atrial arrhythmia, 2) production of ventricular arrhythmia, or increase in number
of ectopic beats, 3) heart block, and 4) asystole.
The use of lidocaine is not advised in the presence
of heart block.
Procainamide. Procainamide is more prone to
produce direct cardiac toxicity expressed as alterations in electrical and mechanical behavior of the
heart than lidocaine. As with lidocaine, many of
the toxic reactions seen with procainamide are
related to size of dose and also to the route of
administration. Rapid intravenous administration,
particularly when given faster than 50-75 mg per
minute, has been associated with undesirable electrocardiographic and hemodynamic effects. Because of
this, oral and intramuscular use of procainamide has
been advocated. However, even with these routes
of administration and recommended dose size, toxicity may be encountered in congestive heart failure,
renal disease, or shock.
In our experience, therapeutic effectiveness and
toxicity of procainamide are closely related to
plasma drug concentration. We consider the effective antiarrhythmic plasma drug concentration range
to be 3 or 4-10 µ,g per ml and have observed electro~hysiologic and hemodynamic toxicity at concentrations greater than 12 µ,g per ml. Notwithstanding
the bad reputation of intravenously administered
procainamide, we have found that antiarrhythmic
plasma drug concentrations are attained rapidly,
~afely, and predictably when procainamide is given
int~avenously. We recommend 100 mg of procainamide be given intravenously every 5 minutes with
electrocardiographic and blood pressure monitoring.
An example of this method is shown in figure 4 ·
the eIectrocard1ogram
.
was continuously monitored'
and p r
.
a 1ent P.B. was given l 00 mg of procainamide
every 5 minutes until VPD's were abolished. Plasma
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samples taken 4 1/2 minutes after each dose indicate
there is a direct linear relationship between cumulative dose and plasma drug concentration. Moreover,
after each procainamide injection, the number of
VPD's diminishes until the sixth dose when the
arrhythmia is completely abolished and a plasma
drug concentration within the therapeutic range
( 8.3 µ,g per ml) is achieved. Neither untoward
hemodynamic nor electrocardiographic effects were
encountered during the course of treatment.
Even at low plasma drug concentration range,
procainamide produces electrocardiographic changes
resulting from its cardiac electrophysiologic actions.
The P-R, QRS, and QT intervals are all prolonged
at therapeutic plasma concentrations. In addition,
toxic drug concentrations have been associated with
progression of these or appearance of more dramatic
electrophysiologic effects such as : l) suppression
of cardiac automaticity, including the S-A node, leading to asystole, 2) impairment of A-V conduction,
leading to heart block, and 3) slowing of intraventricular conduction greater than 30%. Another
noteworthy undesirable electrocardiographic change
stems from the fact that toxic concentrations of
procainamide almost invariably cause increased
automaticity and multifocal pacemaker activity in
isolated cardiac Purkinje fibers. Thus, the appearance of ectopic ventricular beats, ventricular tachycardi a, or fibrillation in a patient who presumably
has achieved therapeutic drug concentration may
not represent arrhythmia breakthrough but rather
procainamide toxicity. If the physician is unaware
of this complication, he may continue to administer
procainamide or even increase the dose, not realizing that the drug is responsible for evoking the
arrhythmia. Since therapeutic and toxic drug effects
are so well correlated with electrocardiographic
changes, the electrocardiogram is an excellent way
to monitor procainamide efficacy and, when carefully used, the incidence of toxicity is likely to be
reduced. Because of its depressant effects on A-V
conduction and ventricular automaticity, procainamide is contraindicated in heart block, and cautious
use has been advised in patients with wide QRS
intervals and bundle branch block.
Procainamide may produce hemodynamic
changes by depressing myocardial contractility and
the cardiac output and thereby produce hypotension.
While the severity of these hemodynamic alterations
appears to be related to dose size and rate of administration, they may be further intensified by heart
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disease and congestive heart failure. Although procainamide should be used cautiously in these conditions, they do not preclude therapy. We have noted
that the probability of untoward hemodynamic
effects is minimized by intermittent intravenous injections and by careful monitoring of blood pressure.
If necessary, doses higher than 1000 mg may be
given by this technique without evidence of cardiac
toxicity or hypotension. Procainamide-induced hemodynamic or electrocardiographic toxicity may be
treated by molar sodium lactate and the catecholamines, norepinephrine or isoproterenol.
Extracardiac toxic reactions to procainamide
are most commonly seen during chronic oral
therapy. Gastrointestinal disturbances (nausea, vomiting, diarrhea), and CNS disturbances (mental depression, psychosis, and convulsions) have been
reported. Other toxic effects include skin rash, fever
and chills, and agranulocytosis. Most of these extracardiac reactions subside almost immediately with

discontinuation of the drug, but some may persist
a few days to a few weeks. A syndrome resembling
systemic lupus erythematosis (SLE) characterized
by arthralgia, fever, pleuropneumonic involvement,
and hepatomegaly has occurred frequently in patients on long-term maintenance therapy. Rarely,
adrenal corticosteroids have been required to control unusually tenacious symptoms of SLE. It should
be pointed out that, unlike SLE, the drug induced
SLE-like syndrome produces no permanent damage
in any vital organ system. This and the fact that
aspirin or steroids may control symptoms are important considerations in planning the management
of a patient who has a life-threatening arrhythmia
for which other drugs are ineffective, and who has
developed the SLE-like syndrome. In such a case,
one reasonable course of action is to continue procainamide and control symptoms of the SLE syndrome with salicylates or adrenal corticosteroids.

